Ultromics Secures $55M in Series C Funding to Revolutionize AI-Powered Heart Failure Diagnosis

Ultromics, a trailblazer in precision heart failure detection, proudly announced its latest funding round, successfully raising $55 million to accelerate the evolution of cardiac diagnostic technology. This substantial financial boost will propel Ultromics' groundbreaking work on its flagship platform, EchoGo®, which capitalizes on the capabilities of artificial intelligence and cardiac ultrasound to revolutionize the diagnosis of challenging cardiac diseases. With access to the largest known echocardiography-based heart disease dataset, EchoGo® empowers clinicians to make more precise, efficient, and accurate evaluations—especially during the critical early stages of heart failure such as HFpEF, where timely intervention is crucial. The new funding will support further development and refinement of its innovative diagnostic tools, ensuring that healthcare providers are equipped with advanced methods to combat heart failure and improve patient outcomes. In a collaborative network that includes world-renowned institutions and industry leaders like the Mayo Clinic, Johnson & Johnson, and Pfizer, Ultromics is uniquely positioned to drive significant improvements in cardiac care. This funding marks a critical step in the company’s mission to transform how heart failure is detected and managed, fostering earlier and more effective treatment strategies that can curtail the progression of the disease. For those interested in the intersection of cutting-edge artificial intelligence and lifesaving medical technology, Ultromics continues to be at the forefront of innovation. To learn more about their transformative work, visit https://www.ultromics.com/. Stay updated on the latest advancements by following Ultromics on social media at X: https://x.com/ultromics and on LinkedIn: https://www.linkedin.com/company/ultromics/.